Chun-Pei Cheng1, I-Ying Kuo2, Hakan Alakus3, Kelly A Frazer3, Olivier Harismendy1, Yi-Ching Wang1, Vincent S Tseng1. 1. Department of Computer Science and Information Engineering, National Cheng Kung University, Tainan 701, Taiwan, Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA, Institute of Basic Medical Sciences, National Cheng Kung University, Tainan 701, Taiwan, Department of Pediatrics and Rady Children's Hospital, University of California San Diego, La Jolla, CA 92093, USA, Department of General, Visceral and Cancer Surgery, University of Cologne, Köln, Germany, Institute for Genomic Medicine, University of California San Diego, La Jolla, CA 92093, USA, Department of Pharmacology and Institute of Medical Informatics, National Cheng Kung University, Tainan 701, Taiwan Department of Computer Science and Information Engineering, National Cheng Kung University, Tainan 701, Taiwan, Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA, Institute of Basic Medical Sciences, National Cheng Kung University, Tainan 701, Taiwan, Department of Pediatrics and Rady Children's Hospital, University of California San Diego, La Jolla, CA 92093, USA, Department of General, Visceral and Cancer Surgery, University of Cologne, Köln, Germany, Institute for Genomic Medicine, University of California San Diego, La Jolla, CA 92093, USA, Department of Pharmacology and Institute of Medical Informatics, National Cheng Kung University, Tainan 701, Taiwan. 2. Department of Computer Science and Information Engineering, National Cheng Kung University, Tainan 701, Taiwan, Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA, Institute of Basic Medical Sciences, National Cheng Kung University, Tainan 701, Taiwan, Department of Pediatrics and Rady Children's Hospital, University of California San Diego, La Jolla, CA 92093, USA, Department of General, Visceral and Cancer Surgery, University of Cologne, Köln, Germany, Institute for Genomic Medicine, University of California San Diego, La Jolla, CA 92093, USA, Department of Pharmacology and Institute of Medical Informatics, National Cheng Kung University, Tainan 701, Taiwan. 3. Department of Computer Science and Information Engineering, National Cheng Kung University, Tainan 701, Taiwan, Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA, Institute of Basic Medical Sciences, National Cheng Kung University, Tainan 701, Taiwan, Department of Pediatrics and Rady Children's Hospital, University of California San Diego, La Jolla, CA 92093, USA, Department of General, Visceral and Cancer Surgery, University of Cologne, Köln, Germany, Institute for Genomic Medicine, University of California San Diego, La Jolla, CA 92093, USA, Department of Pharmacology and Institute of Medical Informatics, National Cheng Kung University, Tainan 701, Taiwan Department of Computer Science and Information Engineering, National Cheng Kung University, Tainan 701, Taiwan, Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA, Institute of Basic Medical Sciences, National Cheng Kung University, Tainan 701, Taiwan, Department of Pediatrics and Rady Children's Hospital, University of California San Diego, La Jolla, CA 92093, USA, Department of General, Visceral and Cancer Surgery, University of Cologne, Köln, Germany, Institute for Genomic Medicine, University of California San Diego, La Jolla, CA 92093, USA, Department of Pharmacology and Institute of Medical Informatics, National Cheng Kung University, Tainan 701, Taiwan Department of Computer Science and Information Engineering, National Cheng Kung University, Tainan 701, Taiwan, Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA, Institute of Basic Medical Sciences, National Cheng Kung University, Tainan 701, Taiwan, Department of Pediatrics and Rady Children's Hospital, University of California San Diego, La Jolla, CA 92093, USA, Department of General, Visceral and Cancer Surgery, University of Cologne, Köln, Germany, Institute for Genomic Medicine, University of California San Diego, La Jolla, CA 92093, USA, Department of Ph
Abstract
MOTIVATION: A rapid progression of esophageal squamous cell carcinoma (ESCC) causes a high mortality rate because of the propensity for metastasis driven by genetic and epigenetic alterations. The identification of prognostic biomarkers would help prevent or control metastatic progression. Expression analyses have been used to find such markers, but do not always validate in separate cohorts. Epigenetic marks, such as DNA methylation, are a potential source of more reliable and stable biomarkers. Importantly, the integration of both expression and epigenetic alterations is more likely to identify relevant biomarkers. RESULTS: We present a new analysis framework, using ESCC progression-associated gene regulatory network (GRN escc), to identify differentially methylated CpG sites prognostic of ESCC progression. From the CpG loci differentially methylated in 50 tumor-normal pairs, we selected 44 CpG loci most highly associated with survival and located in the promoters of genes more likely to belong to GRN escc. Using an independent ESCC cohort, we confirmed that 8/10 of CpG loci in the promoter of GRN escc genes significantly correlated with patient survival. In contrast, 0/10 CpG loci in the promoter genes outside the GRN escc were correlated with patient survival. We further characterized the GRN escc network topology and observed that the genes with methylated CpG loci associated with survival deviated from the center of mass and were less likely to be hubs in the GRN escc. We postulate that our analysis framework improves the identification of bona fide prognostic biomarkers from DNA methylation studies, especially with partial genome coverage.
MOTIVATION: A rapid progression of esophageal squamous cell carcinoma (ESCC) causes a high mortality rate because of the propensity for metastasis driven by genetic and epigenetic alterations. The identification of prognostic biomarkers would help prevent or control metastatic progression. Expression analyses have been used to find such markers, but do not always validate in separate cohorts. Epigenetic marks, such as DNA methylation, are a potential source of more reliable and stable biomarkers. Importantly, the integration of both expression and epigenetic alterations is more likely to identify relevant biomarkers. RESULTS: We present a new analysis framework, using ESCC progression-associated gene regulatory network (GRN escc), to identify differentially methylated CpG sites prognostic of ESCC progression. From the CpG loci differentially methylated in 50 tumor-normal pairs, we selected 44 CpG loci most highly associated with survival and located in the promoters of genes more likely to belong to GRN escc. Using an independent ESCC cohort, we confirmed that 8/10 of CpG loci in the promoter of GRN escc genes significantly correlated with patient survival. In contrast, 0/10 CpG loci in the promoter genes outside the GRN escc were correlated with patient survival. We further characterized the GRN escc network topology and observed that the genes with methylated CpG loci associated with survival deviated from the center of mass and were less likely to be hubs in the GRN escc. We postulate that our analysis framework improves the identification of bona fide prognostic biomarkers from DNA methylation studies, especially with partial genome coverage.
Authors: Elfriede Bollschweiler; Stephan E Baldus; Wolfgang Schröder; Paul M Schneider; Arnulf H Hölscher Journal: J Surg Oncol Date: 2006-10-01 Impact factor: 3.454
Authors: Diana L Mandelker; Keishi Yamashita; Yutaka Tokumaru; Koshi Mimori; David L Howard; Yoichi Tanaka; Andre Lopes Carvalho; Wei-Wen Jiang; Hannah Lui Park; Myoung Sook Kim; Motonobu Osada; Masaki Mori; David Sidransky Journal: Cancer Res Date: 2005-06-01 Impact factor: 12.701
Authors: Myoung Sook Kim; Keishi Yamashita; Young Kwang Chae; Yutaka Tokumaru; Xiaofei Chang; Marianna Zahurak; Motonobu Osada; Hannah Lui Park; Alice Chuang; Joseph A Califano; David Sidransky Journal: Clin Cancer Res Date: 2007-11-15 Impact factor: 12.531
Authors: Qinghua Cui; Yun Ma; Maria Jaramillo; Hamza Bari; Arif Awan; Song Yang; Simo Zhang; Lixue Liu; Meng Lu; Maureen O'Connor-McCourt; Enrico O Purisima; Edwin Wang Journal: Mol Syst Biol Date: 2007-12-18 Impact factor: 11.429
Authors: Alana L Cutliffe; Sharon L McKenna; Darshan S Chandrashekar; Alvin Ng; Ginny Devonshire; Rebecca C Fitzgerald; Tracey R O'Donovan; John J Mackrill Journal: Explor Target Antitumor Ther Date: 2021-12-31